On the heels of similar investment pledges from Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to the ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Lilly’s recently-launched direct-to-consumer campaign also embraces a digital-first approach to reach eczema patients.

Weight loss platform Noom launched a full-page print ad in The Wall Street Journal this week, calling on policymakers to create new guidance around expensive drugs, as compounded GLP-1s are set to be ...

When combined with funding from previously reported warrant exercises and ad Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

Advertisement Article continues below this ad The agency’s Committee for Medicinal Products ... patients should get the drugs ...

Eli Lilly (NYSE:LLY) shares dropped in price Wednesday, amid news the company is suing two pharmacies for compounding ...

Eli Lilly is suing two pharmacies for compounding ... Empower in a statement said restricting access to personalized alternatives to commercial drugs is not in the best interest of patients ...